Clinical Trials
11 trialsNCT03300830 2026-05-29
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
National Institutes of Health Clinical Center (CC)
Recruiting
NCT01552434 2026-05-15
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05028621 2026-05-07
Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease
Case Comprehensive Cancer Center
Phase NA Suspended
NCT03717844 2025-11-20
Registry for Adults With Plasma Cell Disorders (PCD's)
UNC Lineberger Comprehensive Cancer Center
Recruiting
NCT05081141 2024-05-07
HHV8 and Solid Organ Transplantation
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Unknown
NCT05283993 2022-04-25
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Peking University First Hospital
Recruiting
NCT01441063 2020-10-27
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02080416 2016-06-10
Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Terminated
NCT00412321 2014-07-01
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
Centocor, Inc.
Phase 1 Completed
NCT00891280 2011-06-15
Dose-escalation Study of Oral CX-4945
Cylene Pharmaceuticals
Phase 1 Unknown
NCT00127569 2007-01-12
Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
French National Agency for Research on AIDS and Viral Hepatitis
Phase 2 Terminated